Clarification on Product Names and Active Ingredients
No, Arnuity Ellipta, Asmanex HFA, and Asmanex Twisthaler are NOT equivalent to fluticasone propionate—they contain different corticosteroid molecules entirely. Arnuity Ellipta contains fluticasone furoate (not fluticasone propionate), while both Asmanex products contain mometasone furoate, making them fundamentally different medications despite all being inhaled corticosteroids.
Active Ingredient Differences
Arnuity Ellipta
- Active ingredient: Fluticasone furoate (a different molecule than fluticasone propionate)
- Fluticasone furoate is structurally distinct from fluticasone propionate, with different pharmacokinetic properties
- Delivered via dry powder inhaler (Ellipta device)
Asmanex HFA and Asmanex Twisthaler
- Active ingredient: Mometasone furoate (completely different corticosteroid)
- Mometasone has distinct receptor binding characteristics and potency compared to fluticasone propionate 1
- Asmanex HFA uses metered-dose inhaler delivery; Twisthaler uses dry powder delivery 2
Fluticasone Propionate Products
- Available as Flovent HFA (MDI) and Flovent Diskus (DPI)
- Fluticasone propionate has high glucocorticoid receptor affinity (KD = 0.5 nmol/L) and is highly lipophilic 3, 4
- Demonstrates 1.5-fold higher receptor affinity than beclomethasone-17-monopropionate and 3-fold higher than budesonide 3
Relative Potency Considerations
While these are not equivalent medications, understanding their relative potencies is clinically important:
- Fluticasone propionate is approximately twice as potent as beclomethasone dipropionate or budesonide on a microgram-per-microgram basis 1, 5
- The DICE study established potency rankings showing fluticasone propionate DPI had a 2.08:1 ratio compared to flunisolide, while budesonide DPI was 3.45:1 1
- Mometasone furoate has comparable receptor affinity to beclomethasone-17-monopropionate (1.5-fold lower than fluticasone propionate) 3
Clinical Implications
When switching between these products, you cannot use equivalent dosing—each requires specific dose conversion based on comparative potency data and clinical response monitoring. 1
- Fluticasone propionate at 100-250 mcg twice daily provides effective control in mild-to-moderate asthma 5
- Maximum recommended fluticasone propionate dosing is 500 mcg twice daily (1000 mcg/day total) to minimize systemic effects including HPA axis suppression 6
- Doses exceeding 1000 mcg/day of fluticasone propionate increase risks of bone loss, adrenal suppression, and growth suppression in children 6
Common Pitfall to Avoid
Do not assume products with similar-sounding names contain the same active ingredient. Fluticasone furoate and fluticasone propionate are different molecules, and mometasone furoate is an entirely separate corticosteroid class. Always verify the actual active ingredient when prescribing or switching inhaled corticosteroids, as potency differences can lead to under- or over-treatment if not properly accounted for 2.